Abstract
Botulinum toxin Type A (BoNTA) is a successful treatment for chronic migraine prophylaxis. We aimed to evaluate the monthly change of effectiveness of BoNTA treatment. A total of 80 patients (70 females and 10 males) with chronic migraine were included. In our study protocol, we applied to 155 U across 31 fixed-sites and if the patient had pain, 40 U dose injections were applied across 8 specific head/neck muscle areas. Headache days and analgesic intake were noted before the BoNTA injection and during the interviews at the first, second, and third months after the BoNTA injection. The mean age was 37.59 ± 7.60 and 87.5% of the patients were female. The mean number of headache days/month before BoNTA was 18.95±2.69, decreasing to 10.55±3.15 days/month in the first month (p<0.001), 9.31±2.43 days/month in the second month (p<0.001), and increased to 11.97±3.27 days/month in the third month (p<0.001). The mean analgesic intake before BoNTA was 11.48±4.68 tablets/month, while it decreased to 6.53±2.72 tablets/month in the first month (p<0.001) and 5.40±2.46 tablets/month in the second month (p<0.001). In the third month, it was 5.85±2.59 tablets/month (p<0.001). There was a significant increase in pain medication use from the second to the third month (p<0.001). In our study, there was a significant reduction in analgesic intake and headache days in the first and second months after BoNTA injection, and an increase was observed in the third month.
Highlights
Migraine is one of the most common neurological diseases[1,2]
The mean number of headache days/month before Botulinum toxin Type A (BoNTA) was 18.95±2.69, it decreased to 10.55±3.15 days/month
We investigated the effectiveness of BoNTA treatment in patients with chronic migraine who underwent BoNTA for the first time and determined the monthly variability of analgesic intake and number of headache days after the injections
Summary
Migraine is one of the most common neurological diseases[1,2]. The prevalence of migraine for the adult population is between 3.3 and 21.9% for women and between 0.7 and 16.1% for men[2]. Most migraineurs have moderate or severe pain and 75% have a reduced ability to function normally during the headache attacks[4]. It often affects patients’ productivity and leads to loss of workdays[5]. The mean number of headache days/month before BoNTA was 18.95±2.69, decreasing to 10.55±3.15 days/month in the first month (p
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
